MC240508: Genomic Surveillance of Bladder Cancer

Overview

About this study

The purpose of this study is to build a comprehensive genomic repository that details the evolution of bladder cancer. By employing WGS-based ctDNA approach testing using Veracyte, the study seeks to better understand tumor behavior, mechanisms of treatment resistance, and predictive biomarkers of response. This repository will aid in elucidating the relationship between tumor genomics and clinical outcomes, providing insights that can inform the development of personalized therapeutic strategies. This is a prospective, exploratory biomarker study that will enroll subjects who have undergone prior biopsy, with available formalin-fixed paraffin-embedded (FFPE) tissue specimens. The study incorporates baseline and follow-up ctDNA assessments to monitor molecular residual disease (MRD) through a tumor-informed WGS-based ctDNA approach developed by Veracyte.

Participation eligibility

Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. There is no guarantee that every individual who qualifies and wants to participate in a trial will be enrolled. Contact the study team to discuss study eligibility and potential participation.

Inclusion Criteria:

  • Subjects will be screened for eligibility based on inclusion and exclusion criteria. This will involve reviewing medical records, pathology reports, and diagnostic imaging to confirm the diagnosis of bladder cancer.

Exclusion Criteria:

  • This study will exclude children, prisoners, pregnant women, fetuses, neonates, and adults lacking capacity to consent (unless a legally authorized representative is available and willing to consent on their behalf). Patients with insufficient tissue or plasma samples for analysis.
  • Vulnerable Groups: While the study does not specifically target vulnerable populations, it does not exclude them based on socio-economic or educational status. Special provisions will be made to ensure informed consent is understood and voluntary, with accommodations provided for non-English speakers, individuals who are unable to read, or those who may be educationally or financially disadvantaged.

Note: Other protocol defined Inclusion/Exclusion Criteria may apply.

Eligibility last updated 2/20/2025. Questions regarding updates should be directed to the study team contact.
 

Participating Mayo Clinic locations

Study statuses change often. Please contact the study team for the most up-to-date information regarding possible participation.

Mayo Clinic Location Status Contact

Scottsdale/Phoenix, Ariz.

Mayo Clinic principal investigator

Parminder Singh, M.D.

Closed-enrolling by invitation

What is this? (?)
"Close"
Not open to everyone who meets the eligibility criteria, but only those invited to participate by the study team.

Contact information:

Cancer Center Clinical Trials Referral Office

(855) 776-0015

More information

Publications

Publications are currently not available